TEACHING OLD MODELS NEW TRICKS:
IMPROVING CURRENT MODELS

Biomarkers of Functional Toxicities: Identification & Assessment of their Translation into Humans
Jean-Pierre Valentin, Senior Director & Head, Safety Pharmacology, AstraZeneca

NEW STUDIES IN CARCIOGENICITY
TESTING: DOING BETTER WITH RODENTS

Interlaboratory Evaluation of Genomic Signatures for Predicting Carcinogenicity in the Rat
Mark Fielden, Ph.D., Senior Scientist, Non-Clinical Drug Safety, Roche Palo Alto

ZEBRAFISH & OTHER ALTERNATIVE
MODELS: THE LATEST AND GREATEST

Zebrafish Assays as Early Safety Pharmacology Screens: Paradigm Shift or Red Herring?
Mark Holbrook, Ph.D., Research Fellow, Global Safety Pharmacology, Global Discipline Leader, Pfizer (Tentative)

Using the 3Rs to Develop Predictive Models for Preclinical Safety Assessment
Anthony Holmes, Ph.D., Program Manager, National Centre for the 3R’s of Animals in Research

The EPA’s Experience in Utilizing Zebrafish Models in Toxicity Testing
Stephanie Padilla, Ph.D., Neurotoxicologist, Cellular & Molecular Toxicology Branch, Neurotoxicology Division, EPA

PANEL: Impact of Zebrafish Assays
Moderator: Ernie Bush, Ph.D., Vice President, Collaborative Projects, Drug Safety Executive Council

FAILING EARLIER: NOVEL APPROACHES TO CREATE BETTER PREDICTABILITY

Predictive Methodologies in Ophthalmic Discovery and Safety
Robert Peiffer, D.V.M., Ph.D., DACVO, Senior Investigator, Merck and Co.

PANEL: Creating More Predictive Animal Models for Toxicity
Moderator: Jack Reynolds, D.V.M., Chairman, Advisory Board, Drug Safety Executive Council

Drug Safety Executive Council

The Drug Safety Executive Council (DSEC) is a peer-to-peer membership of drug safety leaders with the common objective of advancing the development of better and safer medicines worldwide. Membership in DSEC is limited to leaders representing companies who develop small and large molecule pharmaceuticals only.